Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Madrigal Pharmaceuticals Inc (MDGL) has shared an announcement.
Madrigal Pharmaceuticals has announced the FDA’s accelerated approval of Rezdiffra™, a treatment for adults with a specific type of liver disease known as noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis. The approval, which could change based on results from further trials, marks a significant milestone for patients in need of new therapeutic options for this challenging condition.
Learn more about MDGL stock on TipRanks’ Stock Analysis page.